Barclays lowered the firm’s price target on Grifols to EUR 11 from EUR 11.50 and keeps an Equal Weight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GRFS:
- GigaGen presents IND-enabling data, Phase 1 trial strategy for GIGA-564
- Is GRFS a Buy, Before Earnings?
- Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
- Grifols’ Araclon Biotech presents ‘positive’ results from Phase 2 ABvac40 study
- Grifols’ GigaGen grated expansion of contract with U.S. DOD